← American Pharmacists Association (APhA)
FDANonrulemakingFDA-2021-N-0951

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

RIN
—
Last modified
Dec 6, 2021
Comment window
closed 1698d ago
American Pharmacists Association (APhA) filings
1

Activity

American Pharmacists Association (APhA) filed 1 comment on this docket between Dec 6, 2021 and Dec 6, 2021. 8 other organizations filed here. The comment window closed 1698d ago.

What American Pharmacists Association (APhA) filed (1)

Dec 6, 2021· Comment from American Pharmacists Association (APhA)· FDA-2021-N-0951-0047

Please see the attached comments of the American Pharmacists Association (APhA). While APhA shares FDA's commitment to addressing the opioid crisis, we strongly oppose implementation of mandatory opioid prescriber education through a Risk Evaluation and Mitigation (REMS) strategy due to the immense burden it would place on pharmacists and pharmacies to verify that the required education has taken place.

View on regulations.gov →

Abstract

OPEN

View on regulations.gov →

Co-filers (8)

See everyone who commented →